Your browser doesn't support javascript.
loading
Corrigendum to "A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3ß/snail signaling axis" [Genes & Diseases 11 (2024) 479-494].
Bi, Yanran; Zheng, Ruiling; Hu, Jiahao; Shi, Ruiqing; Shi, Junfeng; Wang, Yutao; Wang, Peng; Jiang, Wenyi; Kim, Gyudong; Liu, Zhiguo; Li, Xiaokun; Lin, Li.
Afiliación
  • Bi Y; School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.
  • Zheng R; College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea.
  • Hu J; School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.
  • Shi R; Department of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou 325000, China.
  • Shi J; School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.
  • Wang Y; School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.
  • Wang P; School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.
  • Jiang W; School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.
  • Kim G; School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.
  • Liu Z; College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea.
  • Li X; School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.
  • Lin L; School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China.
Genes Dis ; 11(3): 101168, 2024 May.
Article en En | MEDLINE | ID: mdl-38292171
ABSTRACT
[This corrects the article DOI 10.1016/j.gendis.2023.02.035.].